RDx Bioscience, CEO settle kickback case for $13M
By 
Adrianne Appel2024-01-11T21:50:00
A New Jersey-based clinical laboratory and its chief executive officer agreed to pay more than $13 million to the Department of Justice (DOJ) to settle illegal kickback allegations.
RDx Bioscience and CEO Eric Leykin engaged in a scheme, between 2017 and 2023, to pay five different types of kickbacks designed to induce referrals for lab testing, the DOJ alleged in its settlement agreement published Wednesday.
Under the agreement, RDx and Leykin will pay approximately $10.3 million to the DOJ and $2.9 million to New Jersey, for portions of alleged false claims made to the state’s Medicaid program.
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
News BriefLawsuit: Ex-Panoramic Health assistant GC alleges retaliation linked to CCO supervisor
The former assistant general counsel at Panoramic Health is suing her former employer alleging wrongful termination after flagging safe harbor violations of the Anti-Kickback Statue.
-
News Brief
Atlantic Home Health Care to pay $10M over energy program false claims
Atlantic Home Health Care LLC agreed to pay nearly $10 million as part of a settlement with the Department of Justice addressing the alleged submission of false claims to the Department of Labor’s Energy Employees Occupational Illness Compensation Program.
-
News BriefNursing home chain, owner to pay $45.6M in kickbacks case
Prema Thekkek and the six skilled nursing homes she owned through her company, Paksn, agreed to pay $45.6 million in entering a consent judgment with the Department of Justice to resolve allegations employees paid kickbacks to doctors who brought patients to them.
More from Regulatory Enforcement
-
ArticleSFO head to step down as speculation grows over future of agency
Nick Ephgrave, director of the U.K.’s main anti-corruption enforcement agency, the Serious Fraud Office, will retire at the end of March—about halfway through his appointed five-year term. Experts say he leaves the agency in a lot better position than he joined it in September 2023.
-
News BriefFTC puts GM’s puts connected vehicle data practices under compliance spotlight
The U.S. Federal Trade Commission finalized its order against General Motors and its OnStar subsidiary over the improper usage of geolocation and driving behavior data of drivers.
-
ArticleKaiser plans pay $556M to settle Medicare upcoding allegations
Kaiser Health affiliates have agreed to pay more than $556 million to settle allegations originally made by whistleblowers that they ignored compliance department warnings and unlawfully reworked diagnoses for Medicare patients in order to receive higher payments from the federal government.